Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Evan Wang initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and a price target of $10.

February 21, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Evan Wang initiates coverage on Spruce Biosciences with a Buy rating and a price target of $10.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually leads to increased investor interest and potentially a positive impact on the stock price in the short term. Given the positive outlook and the setting of a price target that may be above current levels, this could lead to bullish sentiment among investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100